N30 Pharmaceuticals Appoints President and CEO
N30 Pharmaceuticals, a clinical stage biopharmaceutical company that develops therapies for cystic fibrosis, appointed Jon Congleton as President and Chief Executive Officer. Congleton, a veteran in the industry, brings more than 25 years experience in senior management and product commercialization to his new position.
Prior to N30 Pharma, Congleton spent 18 years with Teva Pharmaceuticals, Ltd., where he held positions in general management and global strategic marketing, including Senior Vice President of their Central Nervous System Global Franchise, Senior Vice President of the Global Medicines Group, and as General Manager of Teva Neuroscience, Inc.
Echo Therapeutics Announces New President and CEO
Scott W. Hollander is now President and CEO of the medical device company, Echo Therapeutics, which focuses on skin permeation, continuous glucose monitoring and associated technologies. He brings more than 20 years experience working in the medical device and pharmaceutical equipment industries.
He has also worked for the past 15 years in the specialty markets sector, including medical diagnostics, interventional cardiology/radiology and nuclear medicine. Throughout his career, Hollander has held leadership positions, involved in every facet of product commercialization, including but not limited to research, development, sales market and business development. Most recently, Hollander served as Vice President of Business Development for Otsuka Pharmaceuticals and as CEO of Otsuka’s subsidiary company, Interpharma Praha.
The biopharmaceutical company focused on the development and commercialization of targeted antiviral therapies appointed Nathaniel Katz, MD, as Chairman of its Scientific Advisory Board. Dr. Katz, is a global expert in post herpetic neuralgia (PHN) pain management and also serves as President and CEO of Analgesic Solutions, a research, education and consulting firm that deals exclusively with pain therapeutics.
Michael Kavanaugh, MD, was appointed as Chief Scientific Officer and Head of Research and Early Development for the biotechnology company. Prior to CytomX, Dr. Kavanaugh was Senior Vice President and Chief Scientific Officer of Five Prime Therapeutics. Sridhar Viswanathan, PhD was appointed Vice President of Process Sciences and Manufacturing Operations. Dr. Viswanathan, formerly of Perseid Therapeutics, served as Vice President of Process Development and Manufacturing Operations.
The medical device company focused on skin permeation, continuous glucose monitoring and associated technologies hired Alan W. Schoenbart to serve as Chief Financial Officer. Schoenbart brings more than 30 years experience in financial management to the position.
Great Basin Scientific
The molecular diagnostics company welcomed Ronald K. Labrum and Sam Chawla to the Board of Directors. Labrum, Chairman of Suture Express, Inc., and independent director at Wright Medical Group, Inc., has more than 30 years operating experience in the medical technology and supply industry. Chawla, serves as a Portfolio Manager at Perceptive Advisors LLC and also serves on the Board of Directors at the molecular diagnostics company, Response Genetics, Inc.
The early-stage life sciences company recruited Paul Bunn, Jr., MD and Ralph de Vere White, MD, to serve as advisors on its Scientific Advisory Board. As leaders in oncology, both Dr. Bunn and Dr. de Vere White offer valuable and extensive field expertise. Dr. Bunn is an expert and adviser in lung cancer detection and monitoring and a distinguished Professor of Medicine in Medical Oncology at the University of Colorado. Dr. de Vere White serves as the Director of the UC Davis Comprehensive Cancer Center and as a distinguished Professor in the Department of Urology.
The pharmaceutical industry’s rapidly growing marketing agency, Kansas City-based Intouch Solutions, hired Shane Mayer as Vice President, Client Services. He will join the New York office and oversee team members and manage client relations. Previously, Mayer was a Vice President at Havas Lynx.
The marketing agency hired Dane Hartung as Senior Vice President Account & Strategy. During his 20 plus years in the industry, Hartung has worked in global roles at Merck and within different operating companies at J&J. In his new position, he will be responsible for strengthening strategic dialogues that uncover the emotional decisions made about brands.
Sprout Pharmaceuticals, a women’s sexual health company, named co-founder Cindy Whitehead as CEO. Whitehead has more than 20 years experience in brand building, managing high-performing sales companies and leading marketing and corporate communication functions.
John H. Johnson, founder of Plum Brook Advisors, was appointed to Sucampo Pharmaceutical’s Board of Directors. He brings more than 30 years leadership experience in the pharmaceutical and biotechnology industry, holding executive management positions with industry giants such as Johnson & Johnson, Eli Lilly and Company and Pfizer.
The bio-analytical solutions company appointed Veronica G. H. Jordan, PhD, and David R. Schreiber to serve on their Board of Directors. Jordan is an accomplished entrepreneur and leader in international business. Schreiber brings more than 30 years experience in healthcare industry corporate consulting.
Zynerba Pharmaceuticals, a specialty company that develops transdermal synthetic cannabinoid treatments, appointed Richard A. Baron as Vice President and Chief Financial Officer. Previously, Baron was Senior VP and CFO for Globus Medical. He brings more than 30 years leadership experience in the pharma industry.